We are live on ! Find out more
COCH icon

Envoy Medical

22 hedge funds and large institutions have $3.28M invested in Envoy Medical in 2025 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 5 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

9% more capital invested

Capital invested by funds: $3M → $3.28M (+$277K)

0% more funds holding

Funds holding: 22 → 22 (0)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% less ownership

Funds ownership: 10.82% → 10.81% (-0%)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

60% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 5

Holders
22
Holders Change
–
Holders Change %
0%
% of All Funds
0.29%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
1
Increased
2
Reduced
5
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

COCH Hedge Fund Activity: Q2 2025 in Review

22 of the 7,616 institutional investors tracked by Wall St. Rank reported a position in Envoy Medical (COCH) for Q2 2025, worth a combined $3.28M — up 9.2% from $3M a quarter earlier.

Fund positioning in COCH was balanced in Q2 2025: 1 fund opened new positions, 1 closed out, 2 added to existing stakes and 5 trimmed.

The largest buyer was LPL Financial, opening a new position worth an estimated $41.5K. The largest seller was Weiss Asset Management, cutting an estimated $29K.

  • 22 institutional investors held Envoy Medical (COCH) as of Q2 2025, unchanged from Q1 2025.
  • Funds reported $3.28M of Envoy Medical stock for Q2 2025, up 9.2% quarter-over-quarter.
  • 1 fund opened new Envoy Medical positions in Q2 2025 and 1 closed out, a net change of 0 holders.
  • The largest Envoy Medical buyer in Q2 2025 was LPL Financial, an estimated $41.5K added.
  • The largest Envoy Medical seller in Q2 2025 was Weiss Asset Management, an estimated $29K sold.

Based on aggregated 13F filings for Q2 2025.